tirzepatide pancreatitis gallbladder risk How Does Cause Pancreatitis? Mechanisms and Safety Guidance Does Tirzepatide Cause Pancreatitis? Evidence

10.1111/ejn.15611 Eur

But it does resolve

Hepatic Uncommon (0.1% to 1%): Acute gallbladder disease (cholelithiasis, biliary colic, cholecystectomy) Hypersensitivity Common (1% to 10%): Hypersensitivity reactions (e.g., urticaria, eczema) Postmarketing reports : Anaphylaxis, angioedema Immunologic Very common (10% or more): Anti-drug antibodies (up to 51%) Common (1% to 10%): Neutralizing antibodies Local Common (1% to 10%): Injection site reactions Metabolic Very common (10% or more): Hypoglycemia (up to 19%), decreased appetite (up to 11%) Common (1% to 10%): Hyperglycemia Hypoglycemia (glucose level less than 54 mg/dL) occurred more frequently when this drug was used in combination with a sulfonylurea (up to 13% of patients in a clinical trial)

This occurs because cortisol preferentially stimulates adipocyte differentiation and lipid accumulation in visceral depots while promoting protein catabolism in skeletal muscle